Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec;32(6):e14035.
doi: 10.1111/jsr.14035.

The European Insomnia Guideline: An update on the diagnosis and treatment of insomnia 2023

Affiliations
Free article
Review

The European Insomnia Guideline: An update on the diagnosis and treatment of insomnia 2023

Dieter Riemann et al. J Sleep Res. 2023 Dec.
Free article

Abstract

Progress in the field of insomnia since 2017 necessitated this update of the European Insomnia Guideline. Recommendations for the diagnostic procedure for insomnia and its comorbidities are: clinical interview (encompassing sleep and medical history); the use of sleep questionnaires and diaries (and physical examination and additional measures where indicated) (A). Actigraphy is not recommended for the routine evaluation of insomnia (C), but may be useful for differential-diagnostic purposes (A). Polysomnography should be used to evaluate other sleep disorders if suspected (i.e. periodic limb movement disorder, sleep-related breathing disorders, etc.), treatment-resistant insomnia (A) and for other indications (B). Cognitive-behavioural therapy for insomnia is recommended as the first-line treatment for chronic insomnia in adults of any age (including patients with comorbidities), either applied in-person or digitally (A). When cognitive-behavioural therapy for insomnia is not sufficiently effective, a pharmacological intervention can be offered (A). Benzodiazepines (A), benzodiazepine receptor agonists (A), daridorexant (A) and low-dose sedating antidepressants (B) can be used for the short-term treatment of insomnia (≤ 4 weeks). Longer-term treatment with these substances may be initiated in some cases, considering advantages and disadvantages (B). Orexin receptor antagonists can be used for periods of up to 3 months or longer in some cases (A). Prolonged-release melatonin can be used for up to 3 months in patients ≥ 55 years (B). Antihistaminergic drugs, antipsychotics, fast-release melatonin, ramelteon and phytotherapeutics are not recommended for insomnia treatment (A). Light therapy and exercise interventions may be useful as adjunct therapies to cognitive-behavioural therapy for insomnia (B).

Keywords: diagnosis; evidence-based medicine; guideline; insomnia; treatment.

PubMed Disclaimer

References

REFERENCES

    1. AASM (American Academy of Sleep Medicine). (2014). International classification of sleep disorders, 3rd edition. In American Academy of sleep medicine (editor). Rochester, MN.
    1. Abetz, L., Arbuckle, R., Allen, R. P., Garcia-Borreguero, D., Hening, W., Walters, A., Mavraki, E., & Kirsch, J. M. (2006). The reliability, validity and responsiveness of the IRLSSG rating scale and subscales in a clinical-trial setting. Sleep Medicine, 4, 340-349.
    1. Alimoradi, Z., Jafari, E., Broström, A., Ohayon, M. M., Lin, C. Y., Griffiths, M. D., Blom, K., Jernelöv, S., Kaldo, V., & Pakpour, A. H. (2022). Effects of cognitive behavioral therapy for insomnia (CBT-I) on quality of life: A systematic review and meta-analysis. Sleep Medicine Reviews, 64, 101646. https://doi.org/10.1016/j.smrv.2022.101646
    1. Amiri, S., Hasani, J., & Satkin, M. (2021). Effect of exercise training on improving sleep disturbances: A systematic review and meta-analysis of randomized control trials. Sleep Medicine, 84, 205-218.
    1. APA (American Psychiatric Association). (2013). Diagnostic and statistical manual of mental disorders (5th edition: DSM-5). In American Psychiatric Association (editor). DC.

Publication types

MeSH terms